Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Panbela Therapeutics Inc (PBLA)

Panbela Therapeutics Inc (PBLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 5
  • Shares Outstanding, K 4,855
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,260 K
  • EBIT $ -29 M
  • EBITDA $ -29 M
  • 60-Month Beta 1.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -71.13
  • Most Recent Earnings N/A on 11/09/23
  • Next Earnings Date 01/01/26 [--]
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0001 +5,000.00%
on 12/26/25
0.0200 -74.50%
on 12/15/25
-0.0060 (-54.05%)
since 11/26/25
3-Month
0.0001 +5,000.00%
on 12/26/25
0.1500 -96.60%
on 10/02/25
-0.0449 (-89.80%)
since 09/25/25
52-Week
0.0001 +5,000.00%
on 12/26/25
0.4729 -98.92%
on 02/26/25
-0.3249 (-98.45%)
since 12/27/24

Most Recent Stories

More News
Panbela Provides Business Update and Reports Q3 2024 Financial Results

PBLA : 0.0051 (+363.64%)
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024

PBLA : 0.0051 (+363.64%)
Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Expects interim data by early 2024...

PBLA : 0.0051 (+363.64%)
Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

MINNEAPOLIS, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...

PBLA : 0.0051 (+363.64%)
Panbela Schedules Conference Call on, August 15, 2022, to Report 2022 Second Quarter Financial Results

MINNEAPOLIS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...

PBLA : 0.0051 (+363.64%)
PANBELA THERAPEUTICS INVESTOR ALERT - Kuznicki Law PLLC Investigates Panbela Therapeutics, Inc. - PBLA

Kuznicki Law PLLC is investigating the proposed sale of Cancer Prevention Pharmaceuticals, Inc. to Panbela Therapeutics, Inc. (“the Company”) (NasdaqCM: PBLA). Under the terms of the proposed transaction,...

PBLA : 0.0051 (+363.64%)
Panbela to Host Virtual R&D Day

MINNEAPOLIS, April 27, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing...

PBLA : 0.0051 (+363.64%)
Panbela Announces Poster Presentation at American Association for Cancer Research:

The potential of spermine analogue SBP-101 (diethyl dihydroxyhomospermine) as a polyamine metabolism modulator in ovarian cancer...

PBLA : 0.0051 (+363.64%)
PANBELA THERAPEUTICS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Panbela Therapeutics, Inc. - PBLA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cancer Prevention Pharmaceuticals, Inc. to...

PBLA : 0.0051 (+363.64%)
Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results

MINNEAPOLIS, March 24, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics...

PBLA : 0.0051 (+363.64%)

Business Summary

Panbela Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma,...

See More

Key Turning Points

3rd Resistance Point 0.0149
2nd Resistance Point 0.0130
1st Resistance Point 0.0090
Last Price 0.0051
1st Support Level 0.0031
2nd Support Level 0.0012
3rd Support Level N/A

See More

52-Week High 0.4729
Fibonacci 61.8% 0.2923
Fibonacci 50% 0.2365
Fibonacci 38.2% 0.1807
Last Price 0.0051
52-Week Low 0.0001

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar